Tower View Wealth Management LLC Purchases 2,658 Shares of United Therapeutics Corporation $UTHR

Tower View Wealth Management LLC boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 3,544.0% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,733 shares of the biotechnology company’s stock after acquiring an additional 2,658 shares during the quarter. Tower View Wealth Management LLC’s holdings in United Therapeutics were worth $1,621,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of UTHR. Avoro Capital Advisors LLC lifted its stake in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP increased its position in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC increased its position in shares of United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after acquiring an additional 295,221 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the last quarter. Finally, Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the 3rd quarter worth about $317,617,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Finally, Cantor Fitzgerald upped their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 8,750 shares of United Therapeutics stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $538.15, for a total transaction of $4,708,812.50. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,158,119.40. This trade represents a 31.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $541.55, for a total transaction of $4,494,865.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $24,462,896.60. This trade represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 643,218 shares of company stock valued at $363,705,304. 8.60% of the stock is owned by insiders.

United Therapeutics Stock Performance

United Therapeutics stock opened at $543.39 on Friday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm’s 50-day simple moving average is $561.93 and its 200 day simple moving average is $525.46. The stock has a market cap of $23.07 billion, a PE ratio of 20.06, a price-to-earnings-growth ratio of 1.81 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the business posted $6.63 EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, analysts predict that United Therapeutics Corporation will post 26.49 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.